Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (61-70 of 151) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|October 20, 2022
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b studyAxel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2011
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancerIrfan Kayani, Norbert Avril, Jamshed Bomanji, et al.
European Urology|January 26, 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for CliniciansAxel S Merseburger, Nick Waldron, Maria J Ribal, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
Molecular Cancer Therapeutics|January 28, 2022
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer ModelsValentí Gómez, Myria Galazi, Gregory Weitsman, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
Pageof 16

Showing results (61-70 of 151) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|October 20, 2022
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b studyAxel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
BMC Urology|September 8, 2018
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
BMC Urology|October 5, 2018
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsNeil M Schultz, Neal D Shore, Simon Chowdhury, et al.
European Urology|May 27, 2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancerThomas Powles, Christian Blank, Simon Chowdhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2011
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancerIrfan Kayani, Norbert Avril, Jamshed Bomanji, et al.
European Urology|January 26, 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for CliniciansAxel S Merseburger, Nick Waldron, Maria J Ribal, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
Molecular Cancer Therapeutics|January 28, 2022
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer ModelsValentí Gómez, Myria Galazi, Gregory Weitsman, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
Pageof 16